Zyprexa, the company's potential breakthrough medication for schizophrenia,
is having an ''eye popper'' of a first month on the market. She said that
in October, doctors wrote 13,000 prescriptions for Zyprexa, compared with
the first month for Johnson & Johnson's (JNJ) Risperdal, which had
5,000 in February 1994. Investigators and investors both eagerly anticipate
the results of a head-to-head study of the drugs, to be revealed December
11.